- Home
- CELC vs DADA Comparison
CELC vs DADA Comparison
Compare CELC & DADA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- DADA
- Stock Information
- Founded
- CELC 2011
- DADA 2014
- Country
- CELC United States
- DADA China
- Employees
- CELC N/A
- DADA N/A
- Industry
- CELC Medical Specialities
- DADA Computer Software: Programming Data Processing
- Sector
- CELC Health Care
- DADA Technology
- Exchange
- CELC Nasdaq
- DADA Nasdaq
- Market Cap
- CELC 440.7M
- DADA 480.6M
- IPO Year
- CELC 2017
- DADA 2020
- Fundamental
- Price
- CELC $13.15
- DADA $1.92
- Analyst Decision
- CELC Strong Buy
- DADA Buy
- Analyst Count
- CELC 6
- DADA 6
- Target Price
- CELC $30.17
- DADA $2.73
- AVG Volume (30 Days)
- CELC 184.2K
- DADA 3.9M
- Earning Date
- CELC 03-26-2025
- DADA 03-24-2025
- Dividend Yield
- CELC N/A
- DADA N/A
- EPS Growth
- CELC N/A
- DADA N/A
- EPS
- CELC N/A
- DADA N/A
- Revenue
- CELC N/A
- DADA $1,423,236,152.00
- Revenue This Year
- CELC N/A
- DADA N/A
- Revenue Next Year
- CELC N/A
- DADA $10.67
- P/E Ratio
- CELC N/A
- DADA N/A
- Revenue Growth
- CELC N/A
- DADA N/A
- 52 Week Low
- CELC $10.35
- DADA $1.04
- 52 Week High
- CELC $22.19
- DADA $2.83
- Technical
- Relative Strength Index (RSI)
- CELC 60.85
- DADA 73.01
- Support Level
- CELC $12.55
- DADA $1.83
- Resistance Level
- CELC $13.25
- DADA $1.89
- Average True Range (ATR)
- CELC 0.68
- DADA 0.05
- MACD
- CELC 0.14
- DADA -0.01
- Stochastic Oscillator
- CELC 85.79
- DADA 100.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About DADA Dada Nexus Limited
Dada Nexus provides on-demand retail platform services and fulfillment services to retailers to sell their products, and online advertising and marketing services to its customers such as brand owners or their agents. It also provides last-mile, intracity and intercity delivery services to logistics companies, merchants and individuals on the Dada Now platform. The group fulfills the delivery needs of retailers on JD Now and customers on Dada Now mostly by utilizing registered riders on Dada Now. Dada's average delivery time for on-demand intracity delivery orders was within 30 minutes in 2023, faster than traditional e-commerce where delivery can take days. As of Sept. 16, 2024, JD.com owned 63.2% of Dada Nexus. Dada Nexus competes with Meituan, Ele.me, Douyin, and SF Intra-city.